Global Lip Augmentation Market Poised to Double by 2035 Amid Rising Demand

GlobeNewswire Inc.GlobeNewswire Inc.
|||1 min read
Key Takeaway

Global lip augmentation market expected to double from $7.91B (2025) to $17.37B (2035), driven by social media influence, improved technology, and increased mainstream acceptance.

Global Lip Augmentation Market Poised to Double by 2035 Amid Rising Demand

The global lip augmentation market is expected to expand significantly over the next decade, growing from USD 7.91 billion in 2025 to USD 17.37 billion by 2035, according to market analysis. This expansion represents a compound annual growth rate (CAGR) of 8.21%, reflecting sustained demand for cosmetic enhancement procedures across international markets.

Several factors are contributing to this market trajectory. Social media platforms have amplified beauty trend cycles and consumer interest in cosmetic procedures, while technological innovations in dermal filler formulations have improved safety profiles and results. Additionally, cosmetic procedures have achieved greater mainstream acceptance across broader demographic groups, reducing previous social stigma and expanding the potential customer base.

Dermal fillers maintain dominant market positioning, accounting for 69.69% of the total market share. Within the filler category, hyaluronic acid-based products lead with 74.55% market penetration, reflecting their established efficacy and widespread clinical adoption. These product categories are expected to remain central to market growth throughout the forecast period.

Source: GlobeNewswire Inc.

Back to newsPublished Feb 16

Related Coverage

The Motley Fool

Healthcare's Dividend Gems: Why $ABBV and $BMY Stand Out for Income Investors

$ABBV and $BMY deliver above-average dividend yields and growth, standing out as rare healthcare sector exceptions for patient income investors navigating patent cliffs through innovation.

BMYCELGrABBV
The Motley Fool

AbbVie Stock Trades at Bargain Valuation as New Drugs Offset Humira Decline

AbbVie stock down 11% YTD but trades at 14x forward P/E with 0.49 PEG, suggesting undervaluation amid strong new drug momentum and 3.4% dividend yield.

ABBVXLV
GlobeNewswire Inc.

Lifecore Biomedical Lands Third Commercial Site Transfer in Medical Aesthetics Push

Lifecore Biomedical announces third commercial CDMO site transfer since October 2025, targeting 12% revenue CAGR through 2029.

LFCR
The Motley Fool

SCHD Emerges as Top Dividend Play: ETF Delivers 3.1% Yield With Decade of Growth

Schwab's dividend ETF ($SCHD) combines 3.1% yield with strict quality filters, averaging 12.5% annual returns over ten years through defensive sector exposure.

ABBVKOCVX
The Motley Fool

CVS and AbbVie Emerge as Healthcare Recovery Plays Amid Market Downturn

CVS and AbbVie emerge as recovery opportunities post-market pullback, leveraging diversified operations and immunology momentum respectively, with strong dividend backing investor confidence.

ABBVCVS
The Motley Fool

Two Biotech Darlings Poised for Acquisition: Abivax and Nektar Signal M&A Targets

Abivax and Nektar Therapeutics are positioned as acquisition targets with promising drug candidates and upcoming phase 3 trial data, attracting interest from major pharmaceutical companies.

AMGNABBVLLY